These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

288 related items for PubMed ID: 25836351

  • 1. Relapse in FEV1 Decline After Steroid Withdrawal in COPD.
    Kunz LIZ, Postma DS, Klooster K, Lapperre TS, Vonk JM, Sont JK, Kerstjens HAM, Snoeck-Stroband JB, Hiemstra PS, Sterk PJ, GLUCOLD Study GroupDepartment of Pulmonology, LUMC, Leiden, The Netherlands..
    Chest; 2015 Aug; 148(2):389-396. PubMed ID: 25836351
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effect of fluticasone with and without salmeterol on pulmonary outcomes in chronic obstructive pulmonary disease: a randomized trial.
    Lapperre TS, Snoeck-Stroband JB, Gosman MM, Jansen DF, van Schadewijk A, Thiadens HA, Vonk JM, Boezen HM, Ten Hacken NH, Sont JK, Rabe KF, Kerstjens HA, Hiemstra PS, Timens W, Postma DS, Sterk PJ, Groningen Leiden Universities Corticosteroids in Obstructive Lung Disease Study Group.
    Ann Intern Med; 2009 Oct 20; 151(8):517-27. PubMed ID: 19841453
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Inhaled salmeterol/fluticasone propionate: a review of its use in chronic obstructive pulmonary disease.
    Fenton C, Keating GM.
    Drugs; 2004 Oct 20; 64(17):1975-96. PubMed ID: 15329047
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Health status in the TORCH study of COPD: treatment efficacy and other determinants of change.
    Jones PW, Anderson JA, Calverley PM, Celli BR, Ferguson GT, Jenkins C, Yates JC, Vestbo J, Spencer MD, TORCH investigators.
    Respir Res; 2011 May 31; 12(1):71. PubMed ID: 21627828
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Comparable spirometric efficacy of tiotropium compared with salmeterol plus fluticasone in patients with COPD: a pilot study.
    Bateman ED, van Dyk M, Sagriotis A.
    Pulm Pharmacol Ther; 2008 May 31; 21(1):20-5. PubMed ID: 17118684
    [Abstract] [Full Text] [Related]

  • 11. Effect of fluticasone propionate/salmeterol (250/50 microg) or salmeterol (50 microg) on COPD exacerbations.
    Ferguson GT, Anzueto A, Fei R, Emmett A, Knobil K, Kalberg C.
    Respir Med; 2008 Aug 31; 102(8):1099-108. PubMed ID: 18614347
    [Abstract] [Full Text] [Related]

  • 12. Withdrawal of inhaled glucocorticoids and exacerbations of COPD.
    Magnussen H, Disse B, Rodriguez-Roisin R, Kirsten A, Watz H, Tetzlaff K, Towse L, Finnigan H, Dahl R, Decramer M, Chanez P, Wouters EF, Calverley PM, WISDOM Investigators.
    N Engl J Med; 2014 Oct 02; 371(14):1285-94. PubMed ID: 25196117
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of salmeterol/fluticasone propionate by GOLD stage of chronic obstructive pulmonary disease: analysis from the randomised, placebo-controlled TORCH study.
    Jenkins CR, Jones PW, Calverley PM, Celli B, Anderson JA, Ferguson GT, Yates JC, Willits LR, Vestbo J.
    Respir Res; 2009 Jun 30; 10(1):59. PubMed ID: 19566934
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Predictive factors for evaluation of response to fluticasone propionate/salmeterol combination in severe COPD.
    Tonnel AB, Tillie-Leblond I, Attali V, Bavelele Z, Lagrange O.
    Respir Med; 2011 Feb 30; 105(2):250-8. PubMed ID: 20702076
    [Abstract] [Full Text] [Related]

  • 16. INSTEAD: a randomised switch trial of indacaterol versus salmeterol/fluticasone in moderate COPD.
    Rossi A, van der Molen T, del Olmo R, Papi A, Wehbe L, Quinn M, Lu C, Young D, Cameron R, Bucchioni E, Altman P.
    Eur Respir J; 2014 Dec 30; 44(6):1548-56. PubMed ID: 25359348
    [Abstract] [Full Text] [Related]

  • 17. Early onset of effect of salmeterol and fluticasone propionate in chronic obstructive pulmonary disease.
    Vestbo J, Pauwels R, Anderson JA, Jones P, Calverley P, TRISTSAN study group.
    Thorax; 2005 Apr 30; 60(4):301-4. PubMed ID: 15790985
    [Abstract] [Full Text] [Related]

  • 18. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity.
    van den Berge M, Steiling K, Timens W, Hiemstra PS, Sterk PJ, Heijink IH, Liu G, Alekseyev YO, Lenburg ME, Spira A, Postma DS.
    Thorax; 2014 Jan 30; 69(1):14-23. PubMed ID: 23925644
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Prediction of Long-Term Benefits of Inhaled Steroids by Phenotypic Markers in Moderate-to-Severe COPD: A Randomized Controlled Trial.
    Snoeck-Stroband JB, Lapperre TS, Sterk PJ, Hiemstra PS, Thiadens HA, Boezen HM, Ten Hacken NH, Kerstjens HA, Postma DS, Timens W, Sont JK, GLUCOLD Study Group.
    PLoS One; 2015 Jan 30; 10(12):e0143793. PubMed ID: 26659582
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.